Table 4.

Comparison of efficacy of octreotide versus lanreotide SR in acromegaly

Reference	Number of patients	Octreotide			Lanreotide
		GH normalized	IGF-I normalized	Octrotide dose	GH normalized	IGF-I normalized	Lanreotide dose
Morange 1994	19	16/19	16/19	0.15–0.6 mg/d	8/19	13/19	30 mg/10–14 d
Caron 1997	21	12/21	17/21	0.1–0.6 mg/d	6/22	14/22	30 mg/10–14 d
Colao 1999	45	23/45	23/45	0.15–0.6 mg/d	26/45	26/45	30 mg/10–14 d
Razzore 1999	38	18/38	19/38	0.15–0.6 mg/d	9/38	16/38	30 mg/10–14 d; 60 mg/14 d
Baldelli 2000	95	45/95	32/95	0.1–0.6 mg/d	58/95	72/95	30 mg/10–14 d
Kendall-Taylor 2000	5	4/5	5/5	LAR 20– 30 mg/4 w	4/5	5/5	30 mg/10–14 d
Turner 1999	10	8/10	7/10	LAR 20–30 mg/4 w	7/9	5/9	30 mg/7–10 d
Cozzi 1999	12	4/10	5/10	LAR 10–30 mg/4 w	1/10	4/10	30 mg/7–21 d
Chanson 2000b	125	68%	65%	LAR 20–30 mg/4 w	54%	48%	30 mg/10–14 d
Amato 2002§	20	50%	50%	LAR 10–30 mg/4 w	58%	67%	30 mg/7–10 d

^§Randomized study